Mitotic rate as a predictor for sentinel lymph node positivity in patients with thin melanomas

Kesmodel, Susan B.; Karakousis, G.C.; Terhune, Kyla P.; Canter, Robert J.; Wahl, Peter; Gimotty, Phyllis A.; Guerry, D.; Fraker, Douglas L.; Czerniecki, B. J.; Spitz, Francis R.

doi:10.1007/bf02524003

Cited by 49 publications

(108 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 A recent study showed that a mitotic rate of greater than zero or a thickness greater than 0.76 mm can be associated with positive sentinel lymph nodes in up to 12% of patients. 22 Patients with lesions of similar thickness which were not mitotically active had virtually no metastatic disease. In summation, patients with level II tumors less than 0.76 mm in thickness with an early vertical growth phase, ulceration of the primary tumor, extensive regression, or mitotic activity are at risk for metastatic disease.…”

Section: Early Vertical Growth Phasementioning

confidence: 99%

Prognosticators of melanoma, the melanoma report, and the sentinel lymph node

2006

View full text Add to dashboard Cite

Since the 1960s, the clinical characteristics of melanoma, its histopathology and its biological basis have been the subject of intense study at pigmented lesion clinics in North America, Europe, and Australia. More recently, the immense database of the Melanoma Committee of the American Joint Committee on Cancer (AJCC) has been exploited through complex mathematical models to measure the impact of various histologic features of primary melanomas and of sentinel lymph node deposits and to correlate these parameters with patient survival. The wealth of modern information available to pathologists and clinicians has become of vital interest to the prognostication of the individual patient with melanoma. The purpose of this review is to bring to the attention of anatomic pathologists the essential characteristics of the pathology report for primary cutaneous melanoma in the modern era.

show abstract

Section: Early Vertical Growth Phasementioning

confidence: 99%

Prognosticators of melanoma, the melanoma report, and the sentinel lymph node

2006

View full text Add to dashboard Cite

show abstract

“…[16][17][18][19] When regional nodes are involved, survival rates are roughly halved. However, within stage III, 5-year survival rates range from 20% to 70%, depending primarily on the nodal tumor burden.…”

mentioning

confidence: 99%

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

Coit¹,

Thompson²,

Algazi³

et al. 2016

J Natl Compr Canc Netw

218

167

View full text Add to dashboard Cite

OverviewIn 2016, an estimated 76,380 patients will be diagnosed with and approximately 10,130 patients will die of melanoma in the United States.1 However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically, at an overall rate of 33% for men and 23% women from 2002 to 2006.2 Melanoma is increasing in men more rapidly than any other malignancy, and in women more rapidly than any other malignancy except lung cancer. AbstractThis selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and highdose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted reassessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections. J Natl Compr Canc Netw 2016;14(4):450-473 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.All recommendations are category 2A unless otherwise noted.Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Please NoteThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines ® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network ® (NCCN ® ) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Melanoma are not printed in this issue of JNCCN but can be accessed online at NCCN.org.© National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. Disclosures for the NCCN Melanoma ...

show abstract

“…2,3 Other factors that have been examined variably include patient age, anatomic location, mitotic rate, ulceration, angiolymphatic invasion, lymphangiogenesis, Clark level, vertical growth phase, tumor-infiltrating lymphocytes, regression, and satellitosis. [5][6][7][8][9][10] Differences in study design and data collected no doubt explain some of the variation in factors that reportedly are associated significantly with positive SLN status.…”

mentioning

confidence: 99%

The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma

Paek

Griffith

Johnson

et al. 2006

Cancer

175

106

View full text Add to dashboard Cite

Epithelial growth, branching, and canalization are important morphogenetic events of the rodent ventral prostate (VP) that take place during the first postnatal week. In this study, we evaluated the effect of knocking out MMP‐2 (MMP‐2−/−), by examining developmental and structural aspects of the VP in MMP‐2−/− mice. Neonate (day 6) MMP‐2−/− mice showed fewer epithelial tips, a lower epithelial cell proliferation rate, and also reticulin fiber accumulation. The VP of adult MMP‐2−/− mice showed lower relative weight, smaller epithelial and smooth‐muscle cell volume, and a larger amount of thicker reticulin fibers. No differences in cell proliferation or apoptotic index were noted between adult MMP‐2−/− and wild‐type mice. MMP‐9 was found in the adult MMP‐2−/−, but not in the wild‐type. In conclusion, MMP‐2 function is essential for the epithelial morphogenesis of the mouse VP, and expression of MMP‐9 is not sufficient for acquisition of the normal adult histology. Developmental Dynamics 239:2386–2392, 2010. © 2010 Wiley‐Liss, Inc.

show abstract

Mitotic rate as a predictor for sentinel lymph node positivity in patients with thin melanomas

Cited by 49 publications

References 0 publications

Prognosticators of melanoma, the melanoma report, and the sentinel lymph node

Prognosticators of melanoma, the melanoma report, and the sentinel lymph node

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma

Contact Info

Product

Resources

About